VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify eligible triple-negative breast cancer patients
Roche's assay to be used to find patients eligible for treatment with Tecentriq in combination with Abraxane
Roche's assay to be used to find patients eligible for treatment with Tecentriq in combination with Abraxane
First collaboration product includes medical imaging capabilities to enable more personalized treatment decisions in cancer care
The VENTANA ROS1 (SP384) rabbit monoclonal primary antibody is designed to effectively identify elevated ROS1 protein expression
We celebrate the clinical laboratory products that have made the most difference to your lab work or point-of-care testing and reveal our most popular clinical content of the year
3D InSight Human Liver Disease platform provides the most physiologically relevant testing environment for efficacy and safety
Drop by and see SelectScience on booth #724 at this year's AACC conference in Anaheim, California, from August 4-8
Explore the techniques and technologies that are shaping the latest advancements in cancer research
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies
Help us celebrate the best new clinical assays, kits, instruments and devices by casting your vote today
IMMray™ PanCan-d blood-based test for early detection of pancreatic cancer now set for Q3 2020 launch
Mission Bio announces the potential for more impactful, dynamic therapy development and application for those with acute myeloid leukemia (AML)
A mass spec scientist, from a world-renowned clinical pathology laboratory, shares the secrets to their success in this exclusive SelectScience interview
Project to focus on data-driven cell conversions to produce cell therapies with potential application in wound healing, and oncology immunotherapy
The drug works by targeting the protein responsible for the death of heart cells during an attack
Immunology-focused pharma company INmune Bio is set to start first-in-man clinical trials with a promising anti-TNF compound that could revolutionize the treatment of Alzheimer’s disease and related symptoms
Calcium flow tracked in heart muscle fibres in real time
Lonza and AllCells team up to offer an extensive range of hematopoietic primary cells to reach the global scientific community
New research suggests that metal-based chemotherapies eliminate inhibitory components of the immune system
New results suggest the MammaTyper test could predict the likelihood of complete pathologic remission
Five color, high-performance immunohistochemistry multiplexing solution to advance biomarker studies
Olympus AI algorithm could improve clinical pathology classifications